Cleo Diagnostics (ASX:COV) Accounts Payable & Accrued Expense : A$0.20 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Accounts Payable & Accrued Expense?

Cleo Diagnostics's quarterly accounts payable & accrued expense increased from Dec. 2022 (A$0.12 Mil) to Jun. 2023 (A$0.42 Mil) but then declined from Jun. 2023 (A$0.42 Mil) to Dec. 2023 (A$0.20 Mil).

Cleo Diagnostics's annual accounts payable & accrued expense stayed the same from . 20 (A$0.00 Mil) to . 20 (A$0.00 Mil) but then increased from . 20 (A$0.00 Mil) to Jun. 2023 (A$0.42 Mil).

Cleo Diagnostics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Cleo Diagnostics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Accounts Payable & Accrued Expense Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Accounts Payable & Accrued Expense

0.42

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	0.12	0.42	0.20

Cleo Diagnostics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines